In some follow-up studies conducted on antibody drugs that have been on the market for years (such as rituximab (CD20) and trastuzumab (HER2)), it was found that ADCC effect of these antibodies is an important mechanism for tumor killing in vivo. Because the scarcity of existing targets and the difficulty of discovering new targets for immune treatments, some scientists turn their attention to the development of biobetter drugs. For this reason, how to cultivate or refine existing target antibodies is now a hot spot in the field.
Enhancing the ADCC effect of antibody drugs and exerting stronger tumor killing function are essential parts for biobetter drug development. Up to now, two antibody drugs with enhanced ADCC effects have been approved by the FDA, Roche's CD20 antibody Gazyva and Concord-fermented Kirin CCR4 antibody Poteligeo. Here, we summarize the clinical applications of these ADCC⁺ antibodies.
Below are selected examples of ADCC/CDC therapeutic antibodies that are either approved by FDA or currently being developed in clinical settings. We can help to develop a novel ADCC/CDC⁺ antibody to support your antibody drug discovery.
Table 1. ADCC-Enhancing Antibodies Approved or in Clinical Trials
|Obinutuzumab||CD20||Reduced fucosylation||Completed Clinical Trials. FDA Approved for CLL in 2013.|
|Mogamulizumab||CCR4||Afucosylated||Completed Clinical Trials. Approved in Japan for T-Cell Lymphoma. FDA Approved for HKL in 2018.|
|Margetuximab||HER2||Fc Mutagenesis||Phase 3 Clinical Trial (NCT02492711)|
|MOR208||CD19||Fc Mutagenesis||Phase 3 Clinical Trial (NCT02763319)|
|Ublituximab||CD20||Reduced fucosylation||Phase 3 Clinical Trial (NCT02612311)|
|MEDI-551||CD19||Afucosylated||Phase 2 Clinical Trial (NCT01466153)|
|Gatipotuzumab||MUC1||Altered glycosylation||Phase 2 Clinical Trial (NCT01899599)|
|Tomuzotuximab||EGFR||Altered glycosylation||Phase 2 Clinical Trial (NCT02052960)|
|Ocaratuzumab||CD20||Fc Mutagenesis||Phase 2 Clinical Trial (NCT00003874)|
|RO5083945 (GA201)||EGFR||Altered glycosylation||Phase 2 Clinical Trial (NCT01326000)|
|TrasGEX||HER2||Altered glycosylation||Phase 1 Clinical Trial (NCT01409343)|
|KHK4083||OX40||Afucosylated||Phase 2 Clinical Trial (NCT03703102)|
|Lumretuzumab||HER3||Altered glycosylation||Phase 1 Clinical Trial (NCT01918254)|
|SEA-CD40||CD40||Reduced fucosylation||Phase 1 Clinical Trial (NCT02376699)|
*A single representative of the most advanced clinical trial is included.
Creative Biolabs provides luciferase-based ADCC assay. This Jurkat cell based assay is pioneered by Creative Biolabs, and the methodology is very well accepted by the field. See attached ADCC Reporter Assay Protocol for further details.
All products and services are for Research Use Only. Do Not use in humans.
ADCC Assay WT vs AfucoTM Mabs Visit
Antibody Fc Engineering: Towards Better Therapeutics Visit
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.